-+ 0.00%
-+ 0.00%
-+ 0.00%

Tvardi Therapeutics reports Phase 1 data for STAT3 inhibitor prodrug TTI-109 showing improved tolerability

PUBT·07/07/2026 11:01:25
Listen to the news
Tvardi Therapeutics reports Phase 1 data for STAT3 inhibitor prodrug TTI-109 showing improved tolerability
  • Tvardi Therapeutics reported Phase 1 results for STAT3 inhibitor prodrug TTI-109, citing improved tolerability versus TTI-101.
  • Study showed rapid conversion to TTI-101 with dose-proportional exposure above the STAT3 IC50.
  • Exploratory pharmacodynamic analysis showed up to 60% reductions in STAT3-driven immune cell populations including Th17, Tfh, B cells.
  • Company plans to advance TTI-109 into STAT3-driven dermatologic, gastrointestinal diseases, subject to additional funding, pending IND clearance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070700PRIMZONEFULLFEED9757581) on July 07, 2026, and is solely responsible for the information contained therein.